DPP4 and type 2 diabetes mellitus: In this large comparative effectiveness and safety research study of patients with T2D, we evaluated cardiovascular and safety events associated with the initiation of SGLT2i treatment compared with dipeptidyl peptidase 4 inhibitor (DPP-4i), which clearly lack glycosuric adverse effects and are generally considered safe (1) in the overall population and (2) across subgroups of patients with controlled, above-target, or elevated HbA1c levels at baseline.